theratechnologies
announces
financial
results
third
quarter
fiscal
montreal
globe
newswire
theratechnologies
theratechnologies
company
tsx
th
nasdaq
thtx
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
today
announced
financial
results
third
quarter
fiscal
year
ended
august
theratechnologies
recently
made
number
key
business
decisions
expect
build
stronger
foundation
growth
first
announced
intention
pursue
development
tesamorelin
treatment
nash
general
population
decision
based
strong
scientific
evidence
feedback
world
renowned
experts
disease
area
additionally
restructured
sales
infrastructure
better
align
current
environment
position
commercial
medicines
growth
strategic
initiatives
along
early
development
efforts
oncology
represent
tremendous
opportunities
company
going
forward
said
paul
lévesque
president
chief
executive
officer
theratechnologies
revenue
periods
fiscal
thousands
dollars
periods
ended
august
periods
ended
august
egrifta
net
sales
net
sales
revenue
key
business
highlights
development
tesamorelin
treatment
nash
general
population
announcement
made
september
move
forward
phase
clinical
trial
evaluating
tesamorelin
potential
treatment
nonalcoholic
steatohepatitis
nash
general
population
protocol
submitted
food
drug
administration
fda
european
regulatory
agencies
fourth
quarter
submitted
feedback
regulatory
agencies
received
within
days
company
aims
initiate
clinical
trial
early
iv
push
study
evaluating
new
method
administration
trogarzo
iv
push
currently
conducted
taimed
iv
push
currently
conducted
taimed
study
progressing
well
recruitment
patients
completed
fourth
quarter
terms
agreement
taimed
taimed
agreement
theratechnologies
entitled
commercialize
new
method
administration
approved
transition
egrifta
transition
egrifta
sv
completed
august
completed
august
subsequently
transition
impact
net
revenue
vials
original
formulation
returned
quarter
company
expects
corresponding
revenue
replacement
vials
recorded
fourth
quarter
impact
continues
represent
challenge
sales
representatives
part
interactions
healthcare
providers
september
company
announced
change
sales
infrastructure
reallocation
resources
focused
increasing
number
virtual
interactions
educational
events
physicians
theratechnologies
expects
measures
support
efforts
grow
sales
trogarzo
egrifta
sv
going
forward
egrifta
sv
going
forward
company
continues
make
progress
toward
advancing
research
development
pipeline
service
providers
working
theratechnologies
programs
remain
active
research
development
pipeline
theratechnologies
established
robust
promising
pipeline
investigational
medicines
areas
high
unmet
need
tesamorelin
treatment
nash
september
company
announced
intention
pursue
development
tesamorelin
treatment
nash
general
population
theratechnologies
intends
submit
phase
study
protocol
fda
european
regulatory
agencies
fourth
quarter
subject
feedback
regulatory
agencies
enrollment
patients
planned
begin
first
quarter
theratechnologies
plans
use
new
formulation
tesamorelin
known
formulation
phase
clinical
trial
nash
addition
supplemental
biologics
license
application
expected
filed
fda
early
lipodystrophy
using
pen
injector
currently
developed
new
formulation
october
united
states
patent
trademark
office
uspto
issued
patent
directed
treatment
nash
nonalcoholic
fatty
liver
disease
nafld
patients
using
tesamorelin
patent
scheduled
expire
stems
patent
application
filed
march
massachusetts
general
hospital
mgh
theratechnologies
exclusive
license
mgh
patent
investigational
technologytm
treatment
cancer
company
pursuing
development
unique
targeted
oncology
technology
technology
consists
proprietary
conjugates
pdcs
specifically
target
various
cancers
sortilin
receptor
overexpressed
consists
proprietary
conjugates
pdcs
specifically
target
various
cancers
sortilin
receptor
overexpressed
based
positive
preclinical
data
theratechnologies
plans
submit
investigational
new
drug
application
ind
fda
clinical
trial
evaluating
first
investigational
pdc
end
following
ind
approval
company
expects
initiate
phase
clinical
trial
early
theratechnologies
plans
submit
ind
company
second
investigational
pdc
manufacturing
completed
expected
occur
following
initiation
phase
clinical
trial
third
uarter
f
inancial
r
esults
consolidated
revenue
three
periods
ended
august
compared
periods
ended
august
revenue
third
quarter
impacted
items
tighter
inventory
controls
distributor
level
higher
anticipated
rebates
chargebacks
also
impacting
revenues
quarter
returns
original
vials
formulation
removed
market
vials
still
circulation
pulled
pharmacies
company
expects
corresponding
revenue
replacement
vials
egrifta
recorded
fourth
quarter
finally
prescription
growth
impacted
pandemic
changed
pharmaceutical
sales
marketing
paradigm
hospitals
clinics
become
less
accessible
sales
representatives
due
restrictions
led
fewer
interactions
healthcare
professionals
result
implemented
appropriate
actions
address
challenges
different
sales
structure
reallocation
resources
announced
september
increasing
number
virtual
interactions
educational
events
physicians
ensuring
overall
larger
presence
healthcare
community
believe
measures
support
efforts
grow
sales
egrifta
cost
sales
periods
ended
august
cost
sales
compared
periods
ended
august
fiscal
cost
goods
sold
three
periods
compared
periods
previous
year
decrease
cost
goods
sold
mainly
due
lower
sales
offset
higher
proportion
sales
cost
sales
also
included
amortization
asset
three
periods
ended
august
addition
cost
sales
includes
recognize
inventories
net
realizable
value
periods
ended
august
respectively
nil
corresponding
periods
prior
year
includes
period
ended
august
excess
stock
mainly
due
company
decision
switch
patients
actively
commercialize
egrifta
r
expenses
r
expenses
periods
ended
august
amounted
compared
comparable
periods
fiscal
increase
largely
due
development
oncology
platform
formulation
pen
injector
well
regulatory
expenses
increased
medical
education
initiatives
europe
preparation
launch
selling
expenses
selling
expenses
increased
periods
ended
august
compared
periods
last
year
increase
mainly
associated
increased
activities
europe
amortization
intangible
asset
value
egrifta
commercialization
rights
also
included
selling
expenses
recorded
expense
third
quarter
fiscal
compared
quarter
last
year
period
ended
august
period
last
year
general
administrative
expenses
general
administrative
expenses
periods
ended
august
amounted
compared
reported
comparable
periods
fiscal
increase
general
administrative
expenses
mainly
associated
business
growth
increased
activity
europe
increased
administrative
expenses
result
us
registration
listing
common
shares
nasdaq
october
transition
new
ceo
finance
income
finance
income
consisting
interest
income
periods
ended
august
compared
comparable
periods
fiscal
lower
finance
income
due
large
part
decrease
average
interest
rates
decreased
liquidity
position
fiscal
compared
fiscal
finance
costs
finance
costs
periods
ended
august
compared
comparable
periods
fiscal
finance
costs
third
quarter
period
ended
august
represent
interest
respectively
senior
convertible
notes
issued
june
compared
periods
last
year
finance
costs
third
quarter
ended
august
partially
offset
foreign
currency
gain
finance
costs
also
included
accretion
expense
third
quarter
period
ended
august
compared
periods
last
year
adjusted
ebitda
reasons
noted
adjusted
ebitda
month
periods
ended
august
compared
comparable
periods
fiscal
see
financial
measures
net
loss
taking
account
revenue
expense
variations
described
recorded
net
loss
per
share
third
quarter
fiscal
net
loss
per
share
period
ended
august
compared
net
loss
per
share
period
ended
august
net
loss
per
share
compared
period
ended
august
financial
position
periods
ended
august
cash
flow
generated
used
operating
activities
compared
periods
last
year
third
quarter
fiscal
changes
operating
assets
liabilities
positive
impact
cash
flow
changes
mainly
due
decrease
trade
receivables
nine
months
fiscal
changes
operating
assets
liabilities
negatively
affected
cash
flow
compared
comparable
period
fiscal
august
cash
bonds
money
market
funds
amounted
based
management
estimate
current
level
operations
believe
current
liquidity
position
sufficient
finance
operations
foreseeable
future
financial
measures
reconciliation
net
profit
loss
adjusted
earnings
interest
taxes
depreciation
amortization
adjusted
ebitda
adjusted
ebitda
financial
measure
reconciliation
adjusted
ebitda
net
profit
loss
presented
table
use
adjusted
financial
measures
assess
operating
performance
securities
regulations
require
companies
caution
readers
earnings
measures
adjusted
basis
ifrs
standardized
meanings
unlikely
comparable
similar
measures
used
companies
accordingly
considered
isolation
use
adjusted
ebitda
measure
operating
performance
one
period
next
without
variation
caused
certain
adjustments
could
potentially
distort
analysis
trends
business
believe
provides
meaningful
information
financial
condition
operating
results
obtain
adjusted
ebitda
measurement
adding
net
profit
loss
finance
income
costs
depreciation
amortization
lease
inducements
amortization
income
taxes
also
exclude
effects
certain
transactions
recorded
compensation
stock
option
plan
related
reversals
inventories
adjusted
ebitda
calculation
believe
useful
exclude
items
either
expenses
items
influenced
management
short
term
items
impact
core
operating
performance
excluding
items
imply
necessarily
nonrecurring
compensation
costs
component
employee
remuneration
vary
significantly
changes
market
price
company
shares
addition
items
impact
core
operating
performance
company
may
vary
significantly
one
period
another
adjusted
ebitda
provides
improved
continuity
respect
comparison
operating
results
period
time
method
calculating
adjusted
ebitda
may
differ
used
companies
adjusted
ebitda
thousands
dollars
periods
ended
august
periods
ended
august
net
loss
add
deduct
depreciation
amortization
lease
inducements
amortization
finance
costs
finance
income
compensation
inventories
adjusted
ebitda
company
adopted
ifrs
leases
using
modified
retrospective
approach
effective
fiscal
beginning
december
accordingly
comparative
figures
fiscal
restated
result
adjusted
ebitda
includes
adjustments
additional
depreciation
related
asset
period
ended
august
period
fiscal
accretion
expense
lease
liabilities
included
finance
costs
periods
respectively
ended
august
conference
call
details
conference
call
webcast
held
october
et
discuss
results
call
hosted
paul
lévesque
president
chief
executive
officer
theratechnologies
members
management
team
access
call
please
dial
north
america
international
conference
call
also
webcast
live
https
launch
qreg
audio
replay
conference
call
available
dialing
north
america
international
entering
playback
code
theratechnologies
theratechnologies
tsx
th
nasdaq
thtx
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
addressing
unmet
medical
needs
information
theratechnologies
available
company
website
sedar
edgar
information
press
release
contains
statements
information
collectively
statements
within
meaning
applicable
securities
laws
based
management
beliefs
assumptions
information
currently
available
management
identify
statements
terms
may
could
would
outlook
believe
plan
envisage
anticipate
expect
estimate
negatives
terms
variations
statements
contained
press
release
include
limited
statements
regarding
progress
research
development
activities
various
timelines
achieve
certain
milestones
complete
certain
activities
including
related
filing
regulatory
agencies
phase
study
protocol
investigator
new
drug
application
ind
beginning
clinical
trials
part
research
development
activities
revenue
growth
sales
egrifta
securing
appropriate
pricing
widespread
reimbursement
key
european
countries
launch
europe
potential
product
acquisitions
transactions
although
information
contained
press
release
based
upon
company
believes
reasonable
assumptions
light
information
currently
available
investors
cautioned
placing
undue
reliance
information
since
actual
results
may
vary
information
certain
assumptions
made
preparing
statements
include
current
pandemic
limited
effect
company
operations
sales
egrifta
united
states
increase
time
company
commercial
practices
united
states
canada
countries
european
union
found
violation
applicable
laws
use
egrifta
change
respective
current
safety
profile
recall
market
withdrawal
egrifta
occur
laws
regulation
order
decree
judgment
passed
issued
governmental
body
negatively
affecting
marketing
promotion
sale
egrifta
countries
products
commercialized
continuous
supply
egrifta
available
company
relations
suppliers
egrifta
suppliers
capacity
manufacture
supply
egrifta
meet
market
demand
timely
basis
biosimilar
version
egrifta
approved
fda
company
intellectual
property
prevent
companies
commercializing
biosimilar
versions
egrifta
united
states
reimbursed
european
countries
fda
approve
formulation
fda
european
regulatory
agencies
approve
phase
study
protocol
corporation
phase
clinical
trial
develop
tesamorelin
treatment
nash
general
population
company
succeed
conducting
phase
clinical
trial
company
research
development
activities
using
peptides
derived
oncology
platform
yield
positive
results
allowing
development
new
drug
treatment
cancer
data
obtained
company
market
research
potential
market
size
company
products
accurate
company
european
infrastructure
adequate
commercialize
germany
european
countries
company
business
plan
substantially
modified
information
assumptions
subject
number
risks
uncertainties
many
beyond
theratechnologies
control
could
cause
actual
results
differ
materially
disclosed
implied
information
risks
uncertainties
include
limited
related
arising
adverse
impact
pandemic
company
sales
efforts
sales
initiatives
b
capacity
company
suppliers
meet
obligations
company
c
company
research
development
activities
health
company
employees
capacity
rely
resources
well
e
global
trade
company
expectations
regarding
commercialization
egrifta
company
ability
capacity
grow
sales
egrifta
successfully
united
states
europe
company
capacity
meet
supply
demand
products
market
acceptance
egrifta
united
states
europe
continuation
company
collaborations
significant
agreements
existing
commercial
partners
suppliers
ability
establish
maintain
additional
collaboration
agreements
company
success
continuing
seek
maintain
reimbursements
egrifta
payors
united
states
success
pricing
competing
drugs
therapies
may
become
available
company
ability
protect
maintain
intellectual
property
rights
egrifta
tesamorelin
company
success
obtaining
reimbursement
countries
european
union
together
level
reimbursement
company
ability
capacity
commercialize
germany
launch
countries
european
union
company
ability
obtain
approval
fda
formulation
company
ability
obtain
approval
regulatory
agencies
phase
study
protocol
development
tesamorelin
nash
general
population
without
conducting
phase
earlier
study
population
company
ability
successfully
conduct
phase
clinical
trial
using
tesamorelin
treatment
nash
general
population
timeline
complete
trial
company
capacity
develop
proprietary
oncology
platform
obtain
positive
results
therefrom
company
capacity
acquire
new
products
compounds
company
expectations
regarding
financial
performance
including
revenues
expenses
gross
margins
profitability
liquidity
capital
expenditures
income
taxes
company
estimates
regarding
capital
requirements
refer
current
potential
investors
risk
factors
section
annual
information
form
dated
february
available
sedar
edgar
exhibit
report
form
dated
february
theratechnologies
public
filings
reader
cautioned
consider
risks
uncertainties
carefully
put
undue
reliance
statements
statements
reflect
current
expectations
regarding
future
events
speak
date
press
release
represent
expectations
date
undertake
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
except
may
required
applicable
law
media
inquiries
denis
boucher
vice
president
communications
corporate
affairs
communications
investor
inquiries
leah
gibson
senior
director
investor
relations
lgibson
